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Abstract
Background: Falciparum malaria is a significant problem for Afghan refugees in Pakistan. Refugee treatment
guidelines recommended standard three-day chloroquine treatment (25 mg/kg) for first episodes and extended
five-day treatment (40 mg/kg) for recrudescent infections, based on the assumption that a five-day course would
more likely achieve a cure. An in-vivo randomized controlled trial was conducted among refugees with
uncomplicated falciparum malaria to determine whether five-day treatment (CQ40) was more effective than
standard treatment (CQ25).
Methods: 142 falciparum patients were recruited into CQ25 or CQ40 treatment arms and followed up to 60 days
with regular blood smears. The primary outcome was parasitological cure without recrudescence. Treatment
failures were retreated with CQ40. PCR genotyping of 270 samples, from the same and nearby sites, was used to
support interpretation of outcomes.
Results: 84% of CQ25 versus 51% of CQ40 patients experienced parasite recrudescence during follow-up (adjusted
odds ratio 0.17, 95%CI 0.08-0.38). Cure rates were significantly improved with CQ40, particularly among adults.
Fever clearance time, parasite clearance time, and proportions gametocytaemic post-treatment were similar
between treatment groups. Second-line CQ40 treatment resulted in higher failure rates than first-line CQ40
treatment. CQ-resistance marker pfcrt 76T was found in all isolates analysed, while pfmdr1 86Y and 184Y were
found in 18% and 37% of isolates respectively.
Conclusions: CQ is not suitable for first-line falciparum treatment in Afghan refugee communities. The extended-
dose CQ regimen can overcome 39% of resistant infections that would recrudesce under the standard regimen,
but the high failure rate after directly observed treatment demonstrates its use is inappropriate.
Background
During the extended Afghan conflict, waves of refugees
totalling almost three million entered northwest Paki-
s t a na n dm o r et h a no n em i l l i o nr e m a i n[ 1 , 2 ] .M a l a r i a
became a major problem in Afghan refugee camps, due
to overstretched health infrastructure and some camps
being located on marginal land prone to anopheline
mosquito breeding [2]. By the 1990s, malaria among
refugees increased ten-fold to over 100,000 cases per
annum [2]. Approximately 30% of confirmed cases were
due to Plasmodium falciparum and the remainder to
Plasmodium vivax [3]. Chloroquine (CQ) was Pakistan’s
first-line treatment for uncomplicated falciparum
malaria from 1950 to 2007 [3]. It remains first-line
treatment for vivax malaria, so is still used for treating
unconfirmed malaria and falciparum infections unde-
tected by microscopy or misdiagnosed as vivax [2].
The United Nations High Commissioner for Refugees
(UNHCR), following national guidelines, adopted a
three-day CQ treatment course (total 25 mg/kg as 10
mg/kg on Day 0 and Day 1 and 5 mg/kg on Day 2) in
refugee settlements. However, it became apparent dur-
ing the 1990s that CQ was failing [4,5]. Basic health
unit doctors claimed that many refugees stopped taking
CQ tablets once clinical symptoms reduced or only took
them intermittently. Health policy makers assumed that
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to cure infections if given a five-day course. Conse-
quently, MoH Pakistan adopted as policy a five-day
extended CQ course (CQ 40 mg/kg as 10 mg/kg/day on
Days 0-2 and 5 mg/kg/day on Days 3-4) for any refugee
patient returning to a basic health unit (BHU) with
parasitaemia within a few weeks of their first episode.
When this policy was introduced, no in vivo resistance
survey had been undertaken in refugee camps, despite
CQ-resistant falciparum parasites spreading widely in
Pakistan in the 1990s [4-6].
As there was no evidence to support claims of poor
adherence or the efficacy of extended-dose CQ, an
open-label randomized clinical trial was conducted to
determine whether supervised CQ treatment adminis-
tered at 40 mg/kg over five days (CQ40) was more
effective than 25 mg/kg over three days (CQ25) for cur-
ing infections completely without recrudescence [7].
The trial aim was to provide stronger evidence for the
extended-dose CQ (ECQ) treatment or justification for
discontinuing the policy.
Methods
Study design
The primary trial outcome was the proportion of indivi-
duals in each treatment arm that showed clinical and
parasitological cure with no recrudescence. Sample size
was calculated to detect a difference of 15% in cure rate
between CQ25 and CQ40 treatment arms with 95%
confidence and 90% precision, assuming a 20% loss to
follow-up. The surveys were conducted during winter
months to select only recrudescent episodes. Mosquito
densities and malaria transmission drop during Decem-
ber and January, providing little opportunity for trial
participants to receive further infective bites within the
60-day follow-up period [8,9]. Thus, subsequent falci-
parum episodes were regarded as recrudescence.
Two trials, completed in 1998, were conducted in
Baghicha, Kagan and Adizai refugee camps (Figure 1).
In Baghicha and Kagan, 121 patients were recruited into
two treatment groups and followed for 60 days. The 60-
day duration was deliberate to allow sufficient time for
back-to-back 30-day in vivo studies (i.e. sufficient time
for cases to recrudesce following initial CQ treatment
and recrudesce again following second-line CQ treat-
ment). In Adizai camp, 21 patients were recruited per
treatment group and followed for only 28 days. CQ25
patients received standard three-day treatment (CQ 25
m g / k ga s1 0m g / k go nD a y0a n d1 ,a n d5m g / k go n
Day 2). CQ40 patients received extended 5-day treat-
ment (CQ 40 mg/kg as 10 mg/kg/day on Days 0-2 and
5 mg/kg/day on Days 3-4). Dosages were measured in
1/4 CQ tablets of 37.5 mg each to give an average
dosage (range) of 26.2 (25.0, 27.8) mg/kg for the CQ25
arm and 42.1 (40.0, 45.3) mg/kg for the CQ40 arm. All
treatment was directly observed for 30 minutes post-
treatment.
If parasites reappeared during the follow-up period,
patients received CQ40 second-line rescue treatment as
per MoH and UNHCR guidelines. If parasites reap-
peared a further time, patients received single-dose sul-
phadoxine-pyrimethamine (S: 25 mg/kg, P: 1.25 mg/kg)
or mefloquine (25 mg base/kg) treatment. SP and meflo-
quine tablets were manufactured by Roche. Chloroquine
w a sm a n u f a c t u r e db yA v e n t i sa n ds u p p l i e db yt h e
World Health Organization-Special Programme for
Research and Training in Tropical Diseases (TDR). Sam-
ples of P. falciparum for genotyping analysis were taken
at baseline from a clinical trial of CQ and SP conducted
by the authors in Adizai camp and Jalalabad eastern
Afghanistan in 2002 and 2003 (Rowland unpublished).
Patient recruitment and follow-up
Participants were recruited through passive case detec-
tion at BHUs and active case detection in communities.
Individuals with symptomatic falciparum malaria who
met WHO in vivo selection criteria for low to moderate
transmission settings were randomized to either CQ25
or CQ40 groups using randomized lists [10]. Exclusion
criteria were infants under six months, pregnant
women, vivax malaria co-infections, cases with other
febrile illness, parasitaemia outside the range of 1000-
100,000 asexual parasites/μl, or severe malaria. All
patients gave informed consent. Ethical approval was
provided by both UNHCR Health Committee and the
London School of Hygiene & Tropical Medicine Ethics
Committee. The trial was registered at the Clinical
Trials website, reference number NCT01019408 [11].
Local health supervisors collected demographic and
clinical information at enrolment, including weight, tem-
perature, and symptoms. Supervisors directly observed
treatment according to dosing schedules, prepared
blood smears, and recorded temperature and clinical
symptoms daily for the first five days, then every third
day until day 28. Patients in Kagan and Baghicha were
additionally observed every four days until day 60.
Thick and thin blood smears were stained with 3.5%
Giemsa solution and all slides read on day of collection
by a BHU-based microscopist. Trophozoites and game-
tocytes were counted against 200 white blood cells
(WBC) from thick blood smears, assuming a WBC
count of 8,000/μl. A smear was declared negative if no
parasites were seen after examining 100 fields. Slides
were re-examined for accuracy of diagnosis and
recounted by an independent senior microscopist,
blinded to patient, follow-up day, original result, and
outcome. Differences in count were on average no
greater than 5%. Finger-prick blood samples (~200 μL)
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(Day 0) and sent to LSHTM for genetic analysis.
Trial outcomes were treatment failure rates, fever
clearance times (FCT), parasite clearance times (PCT),
and number of recrudescences. Therapeutic responses
were early treatment failure (ETF), late treatment failure
(LTF) and adequate clinical and parasitological response
(ACPR) using standard WHO in vivo criteria [10]. Para-
sitological responses were classified using the WHO S-
RIII scale for comparison with earlier literature from
low transmission settings [10,12].
Statistical analysis
Data was double-entered in Microsoft
®Excel, with range
and consistency checks to reduce transposition error,
a n da n a l y s e du s i n gS t a t a
®11.0. Analysis was conducted
on an intention-to-treat basis. Data from the three study
sites was combined for the first 28 days to calculate
therapeutic outcomes and analyse subsequent malaria
episodes and Kaplan-Meier survival estimates [10]. Data
recorded over 60 days from Baghicha and Kaghan was
used to estimate second-line therapeutic outcomes. A p-
value of < 0.05 was considered significant. Univariate
analysis used Pearson’s chi-square (c
2) tests for propor-
tions and Mann-Whitney U tests for continuous data.
Logistic regression was used to calculate odds ratios
(OR) of treatment success at weekly intervals and differ-
ences between treatment outcomes. Ap r i o r iconfoun-
ders (i.e. camp, gender, weight, age) were adjusted for in
multivariate analysis.
Genetic characterisation
PCR genotyping could not be conducted on patient data
to determine recrudescences as samples were lost in
transit. However, the authors were able to analyse 90
blood samples from falciparum cases in Adizai (the
same camp) and 180 from Jalalabad, Afghanistan, col-
lected shortly afterwards for a clinical trial to character-
ize resistance genotypes (Rowland unpublished). Parasite
DNA was extracted from 270 blood spots collected on
filter paper pre-treatment (Day 0) as described elsewhere
[13]. PCR-sequence specific oligonucleotide probe assays
were used to analyse genetic polymorphism of P. falci-
parum chloroquine-resistance transporter gene (pfcrt)at
codons 72-76 and P. falciparum multidrug resistance
protein-1 (pfmdr1) at codons 86 and 184 [14]. CQ resis-
tance is associated primarily with point mutations in
pfcrt leading to a lysine to threonine change at codon
76 (K76T) while pfmdr1 N86Y and Y184F are thought
to have a modulatory effect [15,16]. The pfcrt 76T and
pfmdr1 86Y alleles may serve as predictive markers for
CQ resistance in non-immune individuals living in low-
transmission areas, while combined pfcrt 76T and
pfmdr1 86Y may be useful molecular markers for resis-
tance to additional drugs, such as amodiaquine (AQ)
[17-19].
Results
Enrolment characteristics
Figure 1 shows the trial profile. Of 163 patients
recruited, 83 were randomized to CQ25 and 80 to
CQ40 treatment groups. Table 1 shows no significant
differences in enrolment characteristics between treat-
ment groups on Day 0.
First-line therapeutic outcomes
No participants were lost to follow up by day 28. Table
2 shows therapeutic and parasitological outcomes using:
Figure 1 Trial profile.
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failure or adequate clinical and parasitological response,
and (b) the parasitological response system of S, RI, RII,
RIII [10,20]. Fever clearance and parasite clearance
times were similar in CQ25 and CQ40 arms (Table 2).
CQ25 provided adequate clinical and parasitological
response (ACPR) in only 13/83 (16%) of patients by day
28, while CQ40 provided 40/80 (50%) ACPR (adjusted
OR 0.17; 95%CI 0.08, 0.38). There were few (7%) early
treatment failures in either treatment group.
CQ40 patients had fewer recrudescences than did
CQ25 patients during the first 28 days. Among CQ40
patients, only one recrudescent episode occurred before
Day 7. Among CQ25 patients, 86% of recrudescence
occurred between days 7 and 28 post-treatment. The
parasitological failure rate was negatively associated with
age, with failure highest among under-fives and lowest
among over-fifteens (Table 2). Within each age band,
failure rates were consistently lower in the CQ40 group
than in the CQ25 group, irrespective of gender or camp.
Figure 2 shows the proportion of patients found posi-
tive during the first seven days of treatment and
the probability of failure among those still positive on
subsequent days. The longer a patient took to clear
parasites the greater the probability of eventual recru-
descence. All cases treated with CQ25 that were still
positive on Day 3 ultimately recrudesced, while all cases
treated with CQ40 still positive on Day 4 ultimately
recrudesced.
Figure 3 shows cumulative incidence of failure during
each week of follow up. Table 3 shows that adjusted
odds of treatment failure remained consistent between
CQ40 and CQ25 groups at each 7-day interval. After
Day 30 there was no further recrudescence in either
group (Figure 3).
Figure 4 shows the proportion of cases gametocytae-
mic and average gametocyte densities at weekly inter-
vals. There was no significant difference in the
proportion gametocytaemic or in geometric mean game-
tocyte density between the two treatment groups at any
stage after treatment.
Second and third-line therapeutic outcomes
Table 4 provides therapeutic results for second-line
treatment. CQ 40 mg/kg administered as second-line
was less effective than as first-line CQ, regardless of
whether first-line treatment was CQ25 or CQ40. Sec-
ond-line CQ40 cured a higher proportion in the former
C Q 4 0g r o u pt h a ni nt h ef o r m e rC Q 2 5g r o u p ,b u tt h i s
difference was not significant (adjusted OR 0.41; 95%CI
0.14, 1.19; p = 0.10). SP administered as third-line pro-
vided 88% (44/50) parasitological cure before the trial
ended at 60 days.
PCR analysis of genetic markers
Table 5 shows the frequency of pfcrt and pfmdr1 point
mutations among isolates from Adizai and Jalalabad.
The chloroquine resistance-associated pfcrt codon 72-76
haplotype SVMNT (Ser-Val-Met-Asn-Thr) was present
in 100% of samples successfully analysed from Adizai
(63) and Jalabad (179). Pfmdr1 86Y was found in 14%
(12/88) of Adizai and 22% (33/151) of Jalalabad samples.
The pfmdr1 184Y allele was found in 27% (22/82) of
Adizai samples and 46% (69/151) of Jalalabad samples.
Discussion
Chloroquine failure rates were higher than anticipated,
and since administration was directly observed, failure
was due to resistance rather than poor adherence. Ana-
lysis showed that with 51% failure in CQ40 and 84%
failure in CQ25, chloroquine is no longer suitable for
falciparum malaria treatment among Afghan refugees,
either as first or second-line with short or extended
regimens, and usage should stop. Second-line CQ40
achieved a higher failure rate than did first-line, demon-
strating lack of suitability for this purpose.
W h i l et h ea u t h o r sw e r eu n a b l et om a k eu s eo fP C R
genotyping to distinguish recrudescent from new infec-
tions, other in vivo trials conducted in the area that did
include genotyping indicated fewer than 5% would be
new infections [21]. The most compelling evidence for
subsequent infections being therapeutic failures is the
Table 1 Enrolment characteristics on day 0, by treatment
group
Demographic characteristics CQ 25 mg/kg CQ 40 mg/kg
Number enrolled 83 80
Camp
Adizai 21 21
Baghicha 44 47
Kaghan 18 12
Mean age in years (SD) 12.9 (11.3) 12.9 (11.3)
Age group
0-5 19 18
6-14 44 44
15+ 20 18
Total female 40 48
Mean weight in kg (SD) 30.1 (16.1) 32.2 (18.5)
Clinical characteristics CQ 25 mg/kg CQ 40 mg/kg
Number (%) with temperature >
37.5°C
37 (45) 42 (53)
Trophozoite density* (range) 5702 (4297-
7566)
6320 (4816-
8295)
Number (%) with gametocytes 38 (46) 28 (35)
Gametocyte density* (range) 140 (82-238) 148 (84-260)
NB: *refers to geometric mean. SD is standard deviation.
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of any new parasitaemias over 60 days of follow up.
The finding of the pfcrt 76T mutation in 100% of iso-
lates analysed is consistent with a low degree of hetero-
geneity in the parasite population, as also shown by
Khatoon et al in isolates from nearby Bannu district
NWFP [15]. The pfcrt 76T allele is strongly associated
with CQ and amodiaquine (AQ) resistance in falciparum
isolates from Asia, Papua New Guinea, Africa, and
South America [9,15]. Pfmdr1 86Y and 184Y alleles,
which are also associated with CQ and AQ resistance,
were present in only a minority of our isolates from
Adizai camp or from Bannu district [15]. In a clinical
trial of AQ in nearby Afghanistan, which also resulted
in high rates of recrudescence, pfmdr1 alleles were not
strongly selected among treatment failures [22]. These
findings indicate that the pfcrt codon 72-76 haplotype
SVMNT present in Pakistan is sufficient by itself (i.e.
without pfmdr1 86Y and 184Y) to cause high-level CQ
and AQ resistance [9,22]. By contrast, in Africa where
the CQ-resistant variant pfcrt codon 72-76 CVIET
appears to be the predominant haplotype, AQ remains
relatively effective [9]. In the one clinical trial in East
Africa where AQ did demonstrate high levels of in vivo
resistance, the CQ-resistant variant CVIET haplotype
was present with pfmdr1 86Y and 184Y alleles which
presumably added to the resistance there [9,23-26].
The rate of parasitological failure was higher after sec-
ond-line than after first-line CQ40 treatment. Recrudes-
cent infections presumably started with higher
proportions of resistant parasites than did initial infec-
tions. However, this cannot explain why the initial
CQ40 course seemed to eliminate around 39% of resis-
tant infections, as indicated by the improved cure rates
over 60 days following initialf i v e - d a y( 5 1 %r e c r u d e s -
cence) as compared to three-day treatment (84%
Table 2 Outcomes on day 28 by treatment group (odds ratios adjusted for age, weight, gender, and camp using
logistic regression).
Outcomes CQ 25 mg/kg CQ 40 mg/kg OR
1 (95%CI)
Total enrolled 83 80
Total lost, excluded, or withdrawn 0 0
Mean days to fever clearance
2 (95% CI) 2.6 (1.9, 3.3) 2.6 (1.9, 3.3)
Mean days to parasite clearance (95% CI) 2.9 (2.6, 3.1) 3.1 (2.8, 3.3)
Treatment outcomes: n = 163 (%)
Adequate clinical and parasitological response 13 (16) 40 (50) 1
Early treatment failure 6 (7) 6 (7) 0.28 (0.07, 1.09)
Late treatment failure*** 64 (77) 34 (43) 0.16 (0.07, 0.35)
Parasitological outcomes: n = 163 (%)
S 13 (16) 39 (49)
RI 60 (72) 40 (50)
RII 10 (12) 1 (1)
First-line treatment success: n = 52 (%)
Complete parasitological cure without recrudescence*** 13 (16) 39 (49) 0.17 (0.08, 0.38)
First-line treatment failures: n = 111 (%)
Age group
0-5 17 (89) 11 (61) 0.18 (0.03, 1.05)
6-14** 38 (86) 24 (55) 0.17 (0.06, 0.50)
15+* 15 (75) 6 (33) 0.17 (0.04, 0.70)
Gender
Male** 35 (81) 15 (47) 0.17 (0.06, 0.51)
Female** 35 (88) 26 (54) 0.19 (0.07, 0.56)
Camp
Adizai 17 (81) 11 (52) 0.26 (0.06, 1.12)
Baghicha** 37 (84) 24 (51) 0.16 (0.06, 0.46)
Kagan 16 (89) 6 (50) 0.23 (0.03, 1.63)
NB:
1OR is odds ratio, comparing CQ40 to CQ25 adjusted for age, weight, gender, and refugee camp using logistic regression.
2FCT (< 37.5C) excludes those
without fever on admission. *< 0.05,**p < 0.01,***p < 0.001
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Page 5 of 9recrudescence). Among this 39%, any resistant parasites
must have been removed by the additional two days of
treatment and did not reappear over the subsequent 60
days. Ursing et al have, in parallel, undertaken clinical
studies with high-dose CQ in Guinea-Bissau [27,28].
They found that high-dose CQ (75 mg/kg as split-dose
over five days) was well-tolerated (as was the 40 mg/kg
administered in the present trial) and 78% of infections
carrying pfcrt 76T were successfully treated compared
to only 34% with 25 mg/kg [27]. This was a higher
treatment success rate than in Pakistan.
While pfcrt 76T was highly prevalent in the Pakistan
samples, pfcrt 76T prevalence in the Guinea-Bissau
population, discussed above, remained stable at a much
lower 25% between the years 1990 and 2005 [27,29].
These contrasts in pfcrt 76T between continents are
likely due to differences in the fitness of resistance
alleles, as the pfcrt 72-76 SVMNT resistance haplotype
dominant in India, Iran, Pakistan and Afghanistan is not
associated with re-emergence of CQ sensitivity or fluc-
tuations in seasonal prevalence shown by the CVIET
haplotype in some parts of Africa [27,28,30-32]. Drug
pressure may also affect stability. If most infections were
treated with a quinoline, pfcrt 76T frequency would
remain high. In the African settings, sensitive parasites
m a yh a v ef o u n dan i c h ei nt h em a n yu n t r e a t e di n f e c -
tions, where their greater fitness would allow them to
compete better than any co-infecting resistant parasites.
It has been more difficult for CVIET-carrying parasites
to gain the same high prevalence in Africa as SVMNT-
carrying parasites have achieved in parts of Asia.
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Figure 3 Cumulative incidence of treatment failure for each
treatment group.
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Figure 2 Parasite clearance rates and probability of treatment failure among cases still positive on daily intervals after treatment
start.
Table 3 Odds ratios of treatment success at weekly
intervals post-treatment, comparing cq 40 mg/kg with cq
25 mg/kg, adjusted for age, weight, gender, and camp
using logistic regression.
Days after treatment start Odds ratio (95% CI) p-value
7 0.20 (0.05, 0.73) 0.02
14 0.18 (0.08, 0.40) < 0.0001
21 0.15 (0.07, 0.31) < 0.0001
28 0.18 (0.09-0.38) < 0.0001
35 0.18 (0.08, 0.39) < 0.0001
NB: OR compares CQ40 to CQ25, adjusted for age, weight, refugee camp, and
gender using logistic regression.
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Page 6 of 9The present trial did not measure adherence, as it
was designed to assess efficacy rather than effective-
ness. Consequently, it cannot challenge the initial
assumption that refugees fail to adhere to either three-
day or five-day courses. However, recent research
demonstrates that with appropriate instructions - as in
a trial of unsupervised 14-day primaquine treatment -
Afghan refugees will adhere to much longer treatment
regimens than the five-day course described here
[22,33]. What is clear from directly-observed treatment
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Figure 4 Percentage of cases gametocytaemic and geometric mean gametocyte density (95%ci) at weekly intervals post-treatment.
Table 4 Parasitological outcomes among 81 treatment failures receiving second-line cq 40 mg/kg categorized by
initial treatment group (odds ratios adjusted for age, weight, gender, and camp using logistic regression and 29 first-
line failures from adizai excluded from analysis as these were treated with sp).
Outcomes CQ 25 mg/kg CQ 40 mg/kg Odds Ratio (95%CI)
Total receiving CQ40 second-line treatment 52 29
Lost, excluded 0 0
Treatment outcomes: n = 81 (%)
Adequate response 9 (17) 10 (34) 1
Early failure (0-3 days) 6 (12) 3 (10) 0.46 (0.09, 2.40)
Late failure (4-28 days) 37 (71) 16 (55) 0.41 (0.13, 1.20)
Second-line treatment success: n = 19 (%)
Complete parasitological cure (0-28 days) 9 (17) 10 (34) 0.41 (0.14, 1.19)
Second-line treatment failures: n = 62 (%)
Age group
0-5 14 (93) 5 (62) 0.12 (0.01, 1.50)
6-14 21 (84) 12 (75) 0.77 (0.14, 4.21)
15+ 8 (67) 2 (33) 0.27 (0.03, 2.45)
Gender
Male 18 (82) 8 (67) 0.44 (0.09, 2.24)
Female 25 (83) 11 (64) 0.37 (0.09, 1.46)
Camp
Baghicha 29 (78) 15 (65) 0.52 (0.16, 1.66)
Kagan 14 (93) 4 (67) 0.14 (0.01 2.05)
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Page 7 of 9is that neither CQ25 nor CQ40 regimens can be justi-
fied, as neither can provide acceptable cure rates given
the high prevalence of CQ-resistant falciparum malaria
n o wi nP a k i s t a n[ 4 , 5 ] .
In Afghanistan, where many refugees have returned,
most malaria cases are still treated with CQ, without
parasitological diagnosis by either microscopy or rapid
diagnostic test [34]. This makes the present study,
though conducted more than ten years ago, still highly
relevant. About 70-90% of cases in Afghanistan are due
to vivax and will respond to CQ. However, most of the
falciparum cases treated with CQ - whether for three
days or longer - are likely to fail [33]. While the total
number of falciparum cases will be small, without effec-
tive treatment these risk developing into severe malaria.
As up to one-fifth of suspected malaria cases arrive at
government clinics with detectable chloroquine present
in their urine, irregular or intermittent treatment with
chloroquine might be common [35]. The need for rou-
tine parasitological diagnosis by microscopy or rapid
diagnostic test to allow differential and, most impor-
tantly, effective treatment for both falciparum and vivax
malaria is paramount in Pakistan and Afghanistan.
Although combination therapy using artesunate-SP
has been adopted as policy for treatment of confirmed
falciparum malaria in Pakistan and Afghanistan, imple-
mentation is patchy and uptake slow [21]. While follow-
up and numbers of SP patients were too few in this trial
to determine significance, the 12% SP failure rate raises
questions about SP’s long-term efficacy. While SP has a
role as combination partner in Pakistan and Afghani-
stan, if administered without artesunate, resistance to SP
may select rapidly [36,37].
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